ALNY Stock - Alnylam Pharmaceuticals, Inc.
Unlock GoAI Insights for ALNY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.25B | $1.83B | $1.04B | $844.29M | $492.85M |
| Gross Profit | $1.92B | $1.52B | $868.60M | $704.14M | $414.80M |
| Gross Margin | 85.6% | 83.0% | 83.7% | 83.4% | 84.2% |
| Operating Income | $-176,885,000 | $-282,175,000 | $-785,072,000 | $-708,652,000 | $-828,438,000 |
| Net Income | $-278,157,000 | $-440,242,000 | $-1,131,156,000 | $-852,824,000 | $-858,281,000 |
| Net Margin | -12.4% | -24.1% | -109.0% | -101.0% | -174.1% |
| EPS | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 4th 2025 | Wolfe Research | Upgrade | Peer Perform | - |
| August 4th 2025 | Oppenheimer | Upgrade | Outperform | $490 |
| July 30th 2025 | Raymond James | Resumed | Outperform | $370 |
| July 21st 2025 | Truist | Initiation | Buy | $385 |
| March 31st 2025 | Redburn Atlantic | Initiation | Buy | $353 |
| March 24th 2025 | JP Morgan | Upgrade | Overweight | $328← $280 |
| November 12th 2024 | Wolfe Research | Downgrade | Underperform | - |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| August 16th 2024 | Goldman | Upgrade | Buy | $370← $198 |
| February 16th 2024 | Goldman | Downgrade | Neutral | $173 |
| February 15th 2024 | Wolfe Research | Initiation | Peer Perform | - |
| December 8th 2023 | Wells Fargo | Initiation | Equal Weight | - |
| October 11th 2023 | Oppenheimer | Downgrade | Perform | - |
| September 29th 2023 | Raymond James | Initiation | Outperform | $208 |
| May 5th 2023 | BMO Capital Markets | Upgrade | Outperform | $250← $200 |
Earnings History & Surprises
ALNYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $1.51 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.56 | $2.90 | +416.9% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-0.54 | $0.32 | +158.9% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.89 | $-0.01 | +98.9% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-0.62 | $0.06 | +109.7% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-0.92 | $-0.50 | +45.5% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-1.07 | $0.56 | +152.3% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-1.12 | $-0.16 | +85.7% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $-1.20 | $-1.10 | +8.3% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-1.34 | $1.15 | +185.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-1.72 | $-2.21 | -28.5% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-1.97 | $-1.40 | +28.9% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-2.13 | $-1.68 | +21.1% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $-1.86 | $-3.32 | -78.5% | ✗ MISS |
Q3 2022 | Jul 28, 2022 | $-1.62 | $-2.29 | -41.4% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $-1.93 | $-2.00 | -3.6% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $-1.47 | $-2.16 | -46.9% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $-1.51 | $-1.72 | -13.9% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $-1.57 | $-1.61 | -2.5% | ✗ MISS |
Latest News
Alnylam Pharma To Invest $250M To Advance siRNA Enzymatic-Ligation Manufacturing Facility
📈 PositiveHealth Canada Approves Alnylam's AMVUTTRA For ATTR Cardiomyopathy
📈 PositiveLeerink Partners Maintains Market Perform on Alnylam Pharmaceuticals, Lowers Price Target to $351
➖ NeutralReported Friday, Nasdaq-100 Index Reconstituted As Alnylam, Ferrovial, Insmed, Monolithic Power, Seagate And Western Digital Join, While Biogen, CDW, GlobalFoundries, Lululemon, ON Semiconductor And Trade Desk Exit
➖ NeutralStifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $508
📈 PositiveAlnylam Pharma Spends $52M to Pay Down Debt Early, Buys Back $34M in Notes to Strengthen Balance Sheet
📈 PositiveAlnylam Pharmaceuticals shares are trading higher after Wells Fargo raised its price target on the stock from $395 to $479 while maintaining an Equal-Weight rating.
📈 PositiveWells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $479
📈 PositiveReported Saturday, Alnylam Pharmaceuticals HELIOS-B Phase 3 Study Of AMVUTTRA Shows Vutrisiran Improved Cardiac Structure And Function In ATTR-CM Patients With Amyloid Regression And Preserved Kidney Function
📈 PositiveRoyalty Pharma acquires royalty interest in Alnylam's AMVUTTRA for $310M
📈 PositiveRoyalty Pharma Acquires Royalty Interest In Alnylam's Amvuttra From Blackstone Life Sciences For $310M
📈 PositivePiper Sandler Reiterates Overweight on Alnylam Pharmaceuticals, Raises Price Target to $489
📈 PositiveBarclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $527
📈 PositiveAlnylam Pharmaceuticals Raises FY2025 Sales Guidance from $3.300B-$3.550B to $3.600B-$3.800B vs $3.526B Est
📈 PositiveAlnylam shares are trading lower after the company disclosed it received a subpoena from the U.S. Attorney seeking documents related to government price reporting for AMVUTTRA, ONPATTRO OXLUMO And GIVLAARI.
📉 NegativeAlnylam Says Received Subpoena From US Attorney Seeking Documents Pertaining To Govt Price Reporting For AMVUTTRA, ONPATTRO OXLUMO And GIVLAARI
📉 NegativeAlnylam Expects To Initiate Phase 2 Trial Of Mivelsiran In Patients With Alzheimer's Disease In Q4 2025
➖ NeutralAlnylam Pharmaceuticals Q3 Adj. EPS $2.90 Beats $0.75 Estimate, Sales $1.249B Beat $977.794M Estimate
📈 PositiveTruist Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $535
📈 PositiveJP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $473
➖ NeutralFrequently Asked Questions about ALNY
What is ALNY's current stock price?
What is the analyst price target for ALNY?
What sector is Alnylam Pharmaceuticals, Inc. in?
What is ALNY's market cap?
Does ALNY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALNY for comparison